ID BIOMEDICAL (IDBE) - News und Infos I - 500 Beiträge pro Seite

[mastermh]

Hallo!

Da es doch immer recht spärlich um die News von ID steht beabsichtige ich mit diesen Thread die News und Infos zusammenzutragen um so die Entwicklung mitzuverfolgen! Ich bin nicht neu in ID, sondern schon lange dabei und mir persönlich gefallen Threads mit zusammengetragenen Infos sehr gut, so muss man nicht immer das ganze Netz durchsuchen! Danke für die Teilnahme! Meinungen sind natürlich ebenfalls Infos(persönliche) *g*!

ID Biomedical (IDBE) Announces First Quarter Results

VANCOUVER, May 29 /PRNewswire/ - ID Biomedical Corporation (TSE: IDB, NASDAQ: IDBE) announced today its results for the quarter ending March 31, 2001. The net loss for the period was $1.0 million ($0.04 per share) as compared to a net loss of $1.8 million ($0.09 per share) for the same period in 2000. The Company`s licensing revenue increased significantly to $0.5 million in the three months ended March 31, 2001 compared to $0.1 million in the comparable period.

3 months ended March 31 3 months ended December 31

2001 2000
---- ----

Total revenue $1,185,733 $180,344

Net loss $1,031,501 $1,764,650

Loss per share $0.04 $0.09


All dollar amounts are in Canadian dollars.

As of March 31, 2001, the Company`s cash balance was approximately $35.6 million compared to $36.7 million as of December 31, 2000.

About ID Biomedical

ID Biomedical Corporation is a North American based biopharmaceutical company focused on the development of proprietary subunit vaccine products based on its platform intranasal adjuvant / delivery technology, Proteosomes(TM). ID Biomedical has also developed a proprietary genomics analysis system, Cycling Probe (TM) Technology.

ID Biomedical is developing subunit vaccines for the prevention of a number of different diseases. The Company`s lead products in clinical development are StreptAvax(TM), a vaccine for the prevention of diseases caused by group A streptococcus and FluINsure(TM), an intranasal vaccine for the prevention of influenza (flu). Additionally, the Company has a number of vaccines in pre-clinical development.

ID Biomedical is licensing Cycling Probe(TM) Technology as well as its broad patents in signal amplification to the genomics and diagnostic industry for further product and technology development. Currently, Applied Biosystems (NYSE: ABI), Mitsubishi Chemical Corporation, Alexon-Trend, a subsidiary of Apogent Technologies, formerly Sybron International (NYSE: AOT), DiscoveRx and Third Wave Technologies (NYSE: TWTI) have obtained rights to ID Biomedical`s patents.

The foregoing information contains so-called forward-looking statements. These include statements about ID Biomedical`s expectations, beliefs, intentions or strategies for the future, which it indicates by words or phrases such as "anticipate", "expect", "intend", "plan", "will", "we believe", "ID Biomedical believes", "management believes" and similar language. All forward-looking statements are based on ID Biomedical`s current expectations and are subject to risks uncertainties and to assumptions made. Important factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include: (i) the ability to successfully complete preclinical and clinical development of its products; ii) the ability to obtain and enforce timely patent and intellectual property protection for its technology and products; iii) the ability to avoid, either by product design, licensing arrangement or otherwise, infringement of third parties` intellectual property; iv) decisions, and the timing of decisions, made by the health regulatory agencies regarding approval of its products for human testing; v) the ability to complete and maintain corporate alliances relating to the development and commercialization of its technology and products, vi) market acceptance of its technology and products, and (vii) the competitive environment and impact of technological change. ID Biomedical bases its forward-looking statements on information currently available to it, and assumes no obligation to update them.

SOURCE ID Biomedical Corporation

ciao mastermh

[mastermh]

ID Biomedical (IDBE) Subsidiary Receives $5.9 Million From Technology Partnerships Canada


VANCOUVER, June 4 /PRNewswire/ - ID Biomedical announced today that it will receive $5.9 million in federal funding from Technology Partnerships Canada (TPC). The funding will be directed through ID Biomedical`s wholly owned subsidiary, Intellivax International. The funding will be targeted toward further development of the Company`s proprietary platform technology, Proteosomes(TM), for the delivery of intranasal subunit vaccines.

Proteosomes(TM) have the potential to change immunization practices by delivering vaccines with an intranasal spray rather than by injection. Vaccines delivered by nasal spray may be better received by children and may also allow for self-administration by adults. In addition, the technology has the potential to provide better immunity due to its ability to stimulate a strong immune response at mucosal surfaces. This could be extremely beneficial since mucous membranes, such as the nose and respiratory tract, are the entry point for 95 percent of infectious diseases.

Dr. Anthony Holler CEO of ID Biomedical, said that the funds will be used to advance the further development of Proteosomes(TM), as well as vaccine products based on this technology platform. "This funding further strengthens our financial resources and will assist us in exploiting the tremendous potential of the Proteosome(TM) technology in a variety of different applications. We have stated our intentions of entering into strategic alliances with third parties to broaden our pipeline of Proteosomes(TM)-based products. This is the first of what we expect will be a number of different arrangements that will be fundamental to ID Biomedical achieving its goal of maximizing the value of this important asset."

Under the agreement, ID Biomedical expects to receive approximately $2 million a year for the next three years. The Company has agreed to pay TPC a percentage of the amounts it receives from the commercialization of products developed under the program. There is a cap on the amount of any such payments.

ciao mastermh

[Jummi]

also mal ein großen kompliment an mastermh. er ist einiger der wenigen die wirkliche highflyer schon vorab erkennen. ( siehe scios ) mach weiter so!
gruß jummi

[C.Ahmann]

@Jummi,

wie lang bist Du denn schon investiert? Ich bin bereits seit Januar letztem Jahr schon dabei!
Was Mastermh macht ist ja ganz nett, aber halt nichts besonderes!

[mastermh]

@c.ahmann

Ich habe diesen Thread eröffnet um mal News zusammenzutragen, die für jeden kompakt zu lesen sind! Nicht wenn neue News kommen gleich wieder ein neuer Thread aufgemacht wird, sondern ergänzt wird bis ca. 50 Beiträge gibt!
Ich bin persönlich noch nicht seit Januar, aber seit März 2000 dabei.


zu IDBE:
der steile Abwärtstrend scheint nun doch überwunden und der Weg sollte nun doch bis $6 frei sein! Hält sich doch bei dem rel. schwachen Umfeld blendend! +2%

ciao mastermh

[bin-sa]

Wann hat ID Biomedical Quartalzahlen ?
und wie sehen die aus ?
Wie seht das mit der Pipline für Produckte aus?

[Doc.Rene]

@ alle Id Bio Fans
Schaut Euch mal den Chart an.Ich denke,es geht noch mal bis auf 3 Euro runter.Es bildet sich eine typische W-Formation aus.Erst dann ist der Weg bis 6 Euro und höher wieder frei.
Bin seit März 2000 mit 500 Stck dabei und lege natürlich bei 3 Euro nochmal nach.Wie ist Eure Meinung zum kommenden Kursverlauf?
Auf steigende Kurse
Doc

[Börsenrini]

Hier siond Neuigkeiten vom 4.+ 24.9.2001:
Was sagt ihr dazu ???????????????????????

4.09.2001
ID Biomedical Gets Payment From Applied Biosystems

VANCOUVER -(Dow Jones)- ID Biomedical Corp.`s (IDBE) licensee, Applied Biosystems Group (ABI), has made an undisclosed payment for the maintenance of its right to use ID Biomedical`s cycling probe technology.
In a press release, ID Biomedical said the cycling probe technology is a proprietary method of signal amplification for the detection of a nucleic acid target.

The license allows Applied Biosystems to use the technology in a number of areas including genomics, high throughput screening and the development of assays to detect nucleic acid sequences.

ID Biomedical is a biopharmaceutical company.

Company Web Site: http://www.idbiomedical.com

-Wendy Tsau, Dow Jones Newswires; 416-306-2100

(This story was originally published by Dow Jones Newswires)


24.09.2001
ID Biomedical Says StreptAvax Trial Fully Enrolled

VANCOUVER -(Dow Jones)- ID Biomedical Corp. (IDBE) has been informed by the Clinical Trials Research Centre that enrollment for its Phase I/II trial is complete and all adult volunteers have received their first dose of StreptAvax, ID Biomedical`s vaccine for the prevention of diseases caused by group A streptococci.
In a news release, the biopharmaceutical company said the current clinical trial is evaluating the safety of, and immune response to, StreptAvax in healthy adults.

With positive results, studies will move directly to examine the safety and immunogenicity of the vaccine in children, it noted. The company said it expects to enroll children of two different age groups to receive StreptAvax: adolescents, age 10-14 years of age; and the target age group for which StreptAvax is being primarily developed, preschool children, three to six years of age.

Group A streptococcus is responsible for common infections that can lead to life threatening diseases including invasive faciitis, rheumatic fever and toxic shock syndrome, the company said.

Company Web Site: http://www.idbiomedical.com

-Carolyn M. King, Dow Jones Newswires; 416-306-2100

(This story was originally published by Dow Jones Newswires)

[Börsenrini]

ID Biomedical Plans Human Testing For Allergy Vaccine

VANCOUVER -(Dow Jones)- ID Biomedical Corp. (IDBE) will advance an allergy vaccine development program towards human testing.
In a news release, ID Biomedical said the allergy vaccine program is based on its proprietary, intranasal adjuvant/delivery platform, Proteosomes.

The company didn`t say when the human testing will begin.

ID Biomedical is a biopharmaceutical company.

Company Web Site: http://www.idbiomedical.com

[Tittenpaula]

weiss jemand warum die idbe so steigt

ich kann nirgendwo news finden

[mastermh]

Hallo! im anderen thread stand es auch schon grob! hier mal mehr und ausführlicher!

ID Biomedical Announces Cycling Probe Technology Selected For Detection Of Biological Warfare Agents



VANCOUVER, Nov. 1 /PRNewswire/ - ID Biomedical Corporation announced today that the Georgia Tech Research Corporation will use ID Biomedical`s proprietary genomics detection platform, Cycling Probe(TM) Technology, in the development of new systems to detect the presence of biological warfare agents. Initial funding for the program will come from the US Department of Defense. The programs will be conducted by The Wallace H. Coulter Department of Biomedical Engineering, a joint program between the Georgia Institute of Technology (Georgia Tech) and Emory University.

Genetic material is present in all living organisms including biological warfare agents. This genetic material contains a "fingerprint" which allows for the identification of the organism with absolute certainty. Cycling Probe Technology is a proprietary method of identifying the genetic "fingerprint" of organisms.

Cycling Probe Technology is one of the few DNA detection methodologies that has been incorporated into a product approved by the U.S. Food and Drug Administration. The product detects the gene responsible for antibiotic resistance in the bacteria, Staphylococcus aureus, (MRSA).

This is the first time ID Biomedical has granted broad rights to use the technology to an academic institution. ID Biomedical has retained rights to sell Cycling Probe Technology-based products that may result from the development programs, or to otherwise license Cycling Probe Technology to commercial parties that may produce products based upon the results. Further details of the agreement were not disclosed.

"We are very pleased to be working with ID Biomedical`s technology," stated Dr. William Ditto, Professor of The Wallace H. Coulter Department of Biomedical Engineering and Principal Investigator. "We are going to need to begin examining new technologies that can rapidly detect the presence of biological or chemical agents in a variety of different settings. The potential for simple and rapid detection, such as is offered with technologies like Cycling Probe Technology, could be an important aspect of any new biosensor."

ID Biomedical has licensed Cycling Probe Technology on a nonexclusive basis to diagnostic and genomics companies to pursue alternative applications of the platform. In fiscal 2000, ID Biomedical generated over US $15 million in cash flow from Cycling Probe Technology licensing activities.

"Rapid and accurate detection of biological warfare agents such as anthrax, plague and smallpox is a cornerstone of limiting illness, death and spreading of these diseases," said Anthony Holler, M.D., ID Biomedical`s Chief Executive Officer. "Currently, the only technologies that can offer the speed and accuracy required are those that identify the genetic fingerprint of the organism. Our Cycling Probe Technology is a genomic detection platform that has the attributes of simplicity, speed, low cost and the potential for automatability, all of which make it particularly attractive for the development of a detection system for biological warfare agents."

About The Wallace H. Coulter Department of Biomedical Engineering at

Georgia Tech and Emory University

Through the Department, which was created in 1997, Georgia Tech and Emory University jointly contribute to and benefit from research in biomedical engineering with the potential for major breakthroughs in medicine, basic science and applied technology. The program, the first partnership of its kind between a public and a private university, is based in both the College of Engineering at Georgia Tech and the School of Medicine at Emory. The program ranks No. 6 nationally in the U.S. News & World Report listing of America`s Best Graduate Schools.

About ID Biomedical

ID Biomedical Corporation is a North American based biotechnology company focused on the development of proprietary subunit vaccine products including those based on its platform intranasal adjuvant/delivery technology, Proteosomes(TM). ID Biomedical has also developed a proprietary genomics analysis system, Cycling Probe (TM) Technology.

ID Biomedical is licensing Cycling Probe Technology as well as its broad patents in signal amplification to the genomics and diagnostic industry for further product and technology development. Currently, Applied Biosystems, Mitsubishi Chemical Corporation, Alexon-Trend, a subsidiary of Apogent Technologies, formerly Sybron International, DiscoveRx and Third Wave Technologies have obtained rights to ID Biomedical`s patents.

ID Biomedical is developing subunit vaccines for the prevention of a number of different diseases. The Company`s lead products in clinical development are StreptAvax(TM), a vaccine for the prevention of diseases caused by group A streptococcus and FluINsure(TM), an intranasally administered vaccine for the prevention of influenza (flu). Additionally, the Company has a number of vaccines in pre-clinical development.

The foregoing information contains so-called forward-looking statements. These include statements about ID Biomedical`s expectations, beliefs, intentions or strategies for the future, which it indicates by words or phrases such as "anticipate", "expect", "intend", "plan", "will", "we believe", "ID Biomedical believes", "management believes" and similar language. All forward-looking statements are based on ID Biomedical`s current expectations and are subject to risks uncertainties and to assumptions made. Important factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include: (i) the ability to successfully complete preclinical and clinical development of its products; ii) the ability to obtain and enforce timely patent and intellectual property protection for its technology and products; iii) the ability to avoid, either by product design, licensing arrangement or otherwise, infringement of third parties` intellectual property; iv) decisions, and the timing of decisions, made by the health regulatory agencies regarding approval of its products for human testing; v) the ability to complete and maintain corporate alliances relating to the development and commercialization of its technology and products; vi) market acceptance of its technology and product; and (vii) the competitive environment and impact of technological change. ID Biomedical bases its forward-looking statements on information currently available to it, and assumes no obligation to update them. SOURCE ID Biomedical Corporation

-0- 11/01/2001

/CONTACT: ID Biomedical Corporation, Dean Linden, 604-431-9314, www.idbiomedical.com; Magnus & Co., Jo Foster, Media Relations, 626-294-1030; Georgia Tech, Larry Bowie, Media Relations, 404-894-6016; To request a free copy of this organization`s annual report, please go to

--------------------------
nur nicht euphrisch werden! mal sehen wie es weitergeht!

ciao mastermh

[Börsenrini]

Hallo !!!
Hier habe ich wieder Neuigkeiten gefunden. Leider ist mein
Englisch nicht so astrein ....vielleicht gibt es ja einen lieben Menschen, der das übersetzen kann !?!

Neuigkeiten vom 13.11.2001
___________________________________________________________
ID Biomedical Files For Canadian Nasal Flu Vaccine Trial

VANCOUVER -(Dow Jones)- ID Biomedical Corp. (IDBE) has filed a clinical trial application with the Biologic & Genetic Therapeutics Directorate of Health Canada to conduct a Phase I Clinical Trial for FluINsure, the company`s intranasally-delivered vaccine to prevent influenza.
In a news release, ID Biomedical said the trial will focus on the safety and immunogenicity of a trivalent version of the vaccine in about 80 healthy adult volunteers.

It said that in two human studies of a monovalent formulation of FluINsure, the vaccine was "well tolerated," and subjects developed influenza-specific antibodies in the blood stream and in nasal secretions.

ID Biomedical is a biotechnology company.

Company Web Site: http://www.idbiomedical.com

-Cheryl Kim, Dow Jones Newswires; 416-306-2100

(This story was originally published by Dow Jones Newswires)
___________________________________________________________

Neuigkeiten von 15.11.2001
___________________________________________________________

ID Biomedical, U.S. Army To Cooperate On Plague Vaccine

VANCOUVER -(Dow Jones)- ID Biomedical Corp. (IDBE) and the U.S. Army Medical Research and Materiel Command, or USAMRMC, will collaborate on the development of a nasal vaccine against the plague, a potential bioterrorism threat.
In a news release, ID Biomedical said the collaboration will focus on developing a nasal vaccine to prevent plague pneumonia, the most highly infectious and most lethal form of the disease resulting from inhalation of plague organisms.

The plague is caused by Yersinia pestis bacteria. Plague pneumonia is highly contagious because large numbers of plague bacteria can rapidly spread person- to-person through coughing and initial symptoms are similar to the flu, the company said. It said there is currently no effective vaccine against the pneumonic form of plague. ID Biomedical`s Proteosome technology, which was initially invented at the Walter Reed Army Institute of Research, "has been specifically designed to create nasal vaccines that elicit protective immune responses at the mucosal surfaces which line the respiratory tract including the nose, throat and lungs. In this way, inhaled biothreat agents can be neutralized, eliminated and prevented from invading the body," it added.

Potential advantages of Proteosome-based vaccines include ease of administration, safety, increased efficacy, ease of manufacturing and stability, it noted.

USAMRMC, Fort Detrick, Md., is the U.S. Army`s medical materiel developer.

ID Biomedical is a biotechnology company.

Company Web Site: http://www.idbiomed.com

-Carolyn M. King, Dow Jones Newswires; 416-306-2100

(This story was originally published by Dow Jones Newswires)

[C.Ahmann]

Ey, die Nachrichten sind schon alt!

[IDJonni]

Ich hoffe, es gibt in Deutschland noch welche, die an dieses Blockbuster-Unternehmen glauben. Bin seid 08/2000 dabei und habe Aktien akkumuliert seit meinem Einstieg. Auf Grund des Kurssprungs am Freitag können wir mit guten News nächste Woche rechnen. Langsam zeigt sich das wahre Potential dieses Unternehmens.
Leider wird hier in Deutschland wenig diskutiert, das Yahoo-Board bietet aber gute Möglichkeiten den aktuellen Entwicklungen zu folgen.
Aber, weiter so mastermh !
Dieses Unternehmen muß weiter publik gemacht werden !

Go IDBE

Gruß IDJonni

[bin-sa]

wann kommen die ouartal zahlen raus ?
und wie weit sind die mit ihren produckten?
wenn man bedenkt wie gut sie gestiegen sind
und noch potenzial nach oben haben.

[mastermh]

hallo!

also da ich mich in letzter zeit doch stark zurückgehalten habe möchte ich mich bei allen bedanken die den thread und insbesonders die aktie nicht vergessen haben! mein studium nimmt zZ doch viel zeit in anspruch! jedoch wurde idbe im aktionär erneut erwähnt und zu den kanadischen toppicks ernannt! und alle die in idbe investiert sind glauben an das unternehmen und wer lust und laune hat sollte sich den artikel im aktionär durchlesen und ich bin nun seid 5/00 dabei und meine entscheidung hat sich gefestigt!

stay happy

ciao mastermh

[kurttilly]

Hallo zusammen, die ID Biomed besitzen!

Bin seit geraumer Zeit in ID Biomed investiert (Empfehlung GBI) und habe endlich den Thread gefunden. Heute tolle Stimmung bei den Bio`s, auch bei ID Biomed. Kann jemand Neuigkeiten dazu sagen?

Gruß kurttilly

[IDJonni]

Hallo IDBEler,

der gestrige Anstieg ist die Erwartung guter Ergebnisse von Streptavax Phase 1. Heute ist ein Artikel im WallStreetJournal mit der Überschrift

"Positive Data expected from ID Bio`s StreptAvax next week"

Ihr wisst hoffentlich, was dies bedeutet für den Kurs !!

Ich erwarte zweistellige Kurse bei positiver Meldung. Es ist aber nur ein Teil dieses Unternehmens.

1. StreptAvax
2. Fluinsure (Ergebnisse Phase 1 wahrscheinlich im 2.Quartal, lt. Tony Holler in der vorgestrigen Präsentation besser und sicherer als Flumist von Aviron).
3. Weitere CPT-Deals
4. Proteosom-Technologie wird lizensiert

Wer bei dieser Aktie einen langen Atem beweist, wird m.E. belohnt werden, das Potential ist vorhanden.

IDBE - Long and strong !

IDJonni

[kurttilly]

Hallo zusammen !

Was ist hier los an Bord? Keine Aktivitäten, ID Biomed ist doch noch nicht vergessen, trotz fallende Kurse an der Nasdaq: ID fällt nicht! Wenn jetzt die Bio`s kommen, steigen wir weiter! Kann jemand Neues über ID Biomed berichten ???

[IDJonni]

Hallo IDBEler,

nachfolgend eine kleine Zusammenfassung der ereidnisreichen Wochen:

1. Streptavax Phase 1 Ergebnisse erfüllen alle Erwartungen, Eintritt in Phase 2 erfolgt in Kürze.

2. FluINsure Phase 1 Ergebnisse erfüllen alle Erwartungen, Eintritt in Phase 2 erfolgt in Kürze.

3. Verlust pro Aktie in 2001 0,51 Can. $, inkl. einer Abschreibung der TWTI-Aktien. Lizenzeinnahmen im ersten Quartal 2002 durch CPT-Technologie ca. 8 Millionen Can. $.

4. IDBE hat im ersten Quartal 2,5 Millionen US $ von Takara Biomedical Group als Meilensteinzahlung für Nutzung der CPT-Technologie erhalten. Weitere Lizenzzahlungen folgen bei Vermarktung des von Takara entwickelten Gen-Tests.

5. IDBE hat in 2001 alle Rechte an dem Tuberkolose-Impfstoff, die sie von der UCLA gekauft hatten, zurückerworben.

Ausblick:
IDBE wird sich auf die Weiterentwicklung der beiden Blockbuster Streptavax u. FluINsure konzentrieren.
Cash ist laut Roth Capital für gute 3 Jahre noch vorhanden, nicht eingerechnet sind hier die zu erwartenden Einnahmen durch Vermarktung der CPT- u. Proteosomtechnologie.
Fraglich ist wie mit den Rechten am TB-Impfstoff weiterverfahren wird (wird ein neuer großer Partner gesucht, der die Entwicklung übernimmt?). Auch die Abschreibung der TWTI-Anteile wirft Fragen auf, wird jetzt Cash gemacht oder hat die Abschreibung bilanztechnische Gründe ? TWTI wartete zuletzt mit positiven Nachrichten auf (Zusammenarbeit mit japanischen Natianol Cancer Centre), nach einem einem ohne Zweifel kräftigen Kursverfall.

Mein Fazit:
IDBE wird seine Cash-Position weiter stärken in 2002 durch weitere Lizenzabkommen mit CPT, der erste Proteosom-Deal ist auch fällig. Somit werden sie es schaffen Streptavax und FluINsure bis Phase 3 zu führen, bevor Verträge mit größeren Partnern zwecks Vermarktung geschlossen werden. Kleine Anmerkung: MedImmune hat Aviron, vornehmlich wegen des Impfstoffes Flumist, der im Moment noch auf Eis liegt wegen Sicherheitsbedenken der FDA, für 1,5 Mrd. US $ gekauft !!!
Deswegen, Aktien liegenlassen und 3 - 4 Jahre warten. Ich kenne keine andere Biotech-Aktie mit so einem großen Potential, vorausgesetzt man ist sich über die allgemeinen Risiken im Biotechbereich bewußt.

Sollte alles gut laufen mit Streptavax u. FluINsure, dann wird uns diese Aktie sehr reich machen.

Gruß

IDJonni

[IDJonni]

Ergänzung zu 5.

Die Rechte waren von IDBE an Aventis verkauft worden. Aventis hat kein Interesse mehr diesen TB-Wirkstoff zu entwickeln.

Gruß

IDJonni

[IDJonni]

Wichtiger Termin im April:

17.04.2002

World Vaccine Congress in Montreal

IDBE ist Sponsor dieses Kongresses und präsentiert die Phase 1 Daten von FluINsure.

Gruß

IDJonni

[kurttilly]

Hallo zusammen, die hier an Bord sind. Kann mir vielleich jemand in kurzen Worten sinngemäß folgende Meldung übersetzen?
Dank im Voraus
kurttilly

ID Biomedical proceeds to Phase II clinical trial of StreptAvax(TM) Alle Nachrichten

15.04. / 16:07



< zurück <



> Archiv >


ID Biomedical Corporation announced today that it has been granted permission by the Biologics and Genetic Therapies Directorate of the Health Products and Foods Branch of Health Canada to conduct a Phase II Clinical Trial of StreptAvax(TM), ID Biomedical``s vaccine for the prevention of infections caused by group A streptococcus. StreptAvax is the only vaccine of its kind being tested in human clinical trials.

Permission was granted based on results from the Phase I Clinical Trial which showed that StreptAvax had a good safety profile and was well tolerated by healthy adult volunteers. Additionally, the Phase I study showed that StreptAvax stimulated broad immune responses against the strains targeted by the vaccine.

StreptAvax is a multivalent recombinant vaccine developed to cover 26 serotypes of group A streptococcus. According to data obtained from the US Centers for Disease Control and Prevention (CDC), these serotypes are believed to be responsible for causing the vast majority of group A streptococcus related diseases.

The randomized and blinded Phase II Clinical Trial will evaluate the safety and immunogenicity of StreptAvax in approximately 70 healthy adult volunteers, and will also enroll approximately 20 adults to receive a licensed hepatitis vaccine on an identical schedule to provide a safety comparison. With positive results, ID Biomedical will proceed to examine the safety and immune response of the vaccine in healthy children. StreptAvax is being developed primarily for use in immunization of pre-school aged children.

The Principal Investigator for the Phase II study will be Dr. Scott Halperin, Professor of Pediatrics at Dalhousie University and also Head of Pediatric Infectious Diseases and Director of the Clinical Trials Research Center (CTRC) at IWK Grace Health Centre. Dr. Halperin is one of North America``s leading clinical researchers in the field of novel vaccines for adult and pediatric populations.

Group A streptococcus is responsible for common infections of the throat ("strep throat``) and skin. Left untreated, these infections can lead to life threatening diseases including invasive faciitis ("flesh eating disease"), rheumatic fever and toxic shock syndrome. In the United States alone it is estimated that there are 25-35 million doctor visits each year for suspected group A streptococcal infections, making it one of the most common childhood illnesses for which no preventative vaccine exists.

About ID Biomedical

ID Biomedical Corporation is a North American based biotechnology company focused on the development of proprietary subunit vaccine products including those based on its platform intranasal adjuvant/delivery technology, Proteosomes(TM). ID Biomedical has also developed a proprietary genomics analysis system, Cycling Probe(TM) Technology.

ID Biomedical is developing subunit vaccines for the prevention of a number of different diseases. The Company``s lead products in clinical development are StreptAvax(TM), a vaccine for the prevention of diseases caused by group A streptococcus and FluINsure(TM), an intranasally administered vaccine for the prevention of influenza (flu). Additionally, the Company has a number of vaccines in pre-clinical development.

ID Biomedical is licensing Cycling Probe Technology as well as its broad patents in signal amplification to the genomics and diagnostic industry for further product and technology development. Several companies have obtained rights to ID Biomedical``s substantial patent portfolio.

About Clinical Trials Research Center

CTRC is research group based in the Department of Pediatrics, Dalhousie University and the IWK Health Centre. CTRC``s physicians, research scientists, nurses, technicians, administrative support staff, and postgraduate trainees, work collectively in various areas of medical research, particularly in the field of infectious diseases, including epidemiological research and clinical trials with drugs and biologics.

CTRC has expertise in the development, management and coordination of multi-centered, multi-national studies.

CTRC investigators can develop, or provide assistance with the development of, studies, protocols, and provide logistical review of study designs. CTRC study coordinators, under the direction of the director and center manager develop case reports forms, ethics package and user manuals. CTRC coordinators are CCRC certified, have extensive experience in site trial coordination and field management, and are knowledgeable in GCP regulatory guidelines.

The foregoing information contains so-called forward-looking statements. These include statements about ID Biomedical``s expectations, beliefs, intentions or strategies for the future, which it indicates by words or phrases such as "anticipate", "expect", "intend", "plan", "will", "we believe", "ID Biomedical believes", "management believes" and similar language. All forward-looking statements are based on ID Biomedical``s current expectations and are subject to risks uncertainties and to assumptions made. Important factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include: (i) the ability to successfully complete preclinical and clinical development of its products; ii) the ability to obtain and enforce timely patent and intellectual property protection for its technology and products; iii) the ability to avoid, either by product design, licensing arrangement or otherwise, infringement of third parties`` intellectual property; iv) decisions, and the timing of decisions, made by the health regulatory agencies regarding approval of its products for human testing; v) the ability to complete and maintain corporate alliances relating to the development and commercialization of its technology and products, vi) market acceptance of its technology and products, and (vii) the competitive environment and impact of technological change. ID Biomedical bases its forward-looking statements on information currently available to it, and assumes no obligation to update them.

Contacts: ID Biomedical Corporation Magnus & Co. Dean Linden Jo Foster Manager, Corporate Communications Media Relations [phone] [phone] www.idbiomedical.com

ID Biomedical Corporation

[kurttilly]

Hallo zusammen! Ist noch jemand in ID Biomedical investiert ???? Kann vielleicht jemand ein Übersetzung bringen ?

Danke im Voraus
kurttilly



FluINsure(TM), stimulated statistically significant mucosal antibody responses - Responses were equal to, or greater than, those reported for live attenuated intranasal influenza vaccines in the same population TRADING SYMBOLS - NASDAQ - "IDBE", TSE - "IDB"

VANCOUVER, July 8 /PRNewswire-FirstCall/ - ID Biomedical Corporation announced today that analysis of nasal antibody levels from the Company``s Phase I Clinical Trial of FluINsure(TM), a novel subunit influenza vaccine for nasal administration, showed that all dose levels of the vaccine tested gave statistically- significant increases in nasal antibodies against the influenza viruses represented in the vaccine. These findings complement the encouraging serum antibody response data that were reported previously from this study.

The Phase I trial was conducted at the Clinical Trials Research Center (CTRC) at Dalhousie University and the IWK Health Centre in Halifax, Nova Scotia by Dr. Scott Halperin, Professor of Pediatrics and the CTRC``s Director. The double-blinded placebo-controlled study focused on the safety and immunogenicity of four escalating doses of FluINsure in 78 healthy adult volunteers.

Louis Fries, M.D., Vice President for Clinical and Regulatory Affairs for ID Biomedical, said, "With this new data, we have expanded our understanding of the immune responses evoked by FluINsure. We were able to demonstrate statistically significant increases in the levels of secretory IgA (sIgA) antibodies in nasal washings that are directed against all three viruses in the trivalent vaccine. These results are very encouraging, especially when coupled to the strong serum antibody responses we reported earlier. There is an increasing appreciation of the role of virus-specific sIgA antibody in the nose and respiratory tract as an important mediator of influenza immunity. We were also pleased to find that, when compared to published data regarding the cold-adapted live virus nasal vaccine in healthy adults, FluINsure induced nasal sIgA responses in at least as great a proportion of subjects, and that the magnitude of these responses was as great as, or greater than, those reported in subjects who received the live vaccine."

Data from the clinical trial will be presented in greater detail by Dr. Halperin at the 42nd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Diego, CA, on 29 September, 2002 (http://www.icaac.org/42ICAAC/Accepts.asp).

FluINsure has recently entered Phase II Trials designed to determine an optimal formulation and dose, and expand its safety and immunogenicity database.

FluINsure is based on the Company``s proprietary Proteosome(TM) vaccine delivery/adjuvant technology. The flu vaccine is created by combining Proteosome proteins with a purified preparation of influenza proteins that includes the hemagglutinin protein. Importantly, unlike some other nasal influenza vaccines in development, FluINsure contains no live viruses. Intranasal vaccines based on the Proteosome delivery system, and incorporating a variety of antigens in addition to influenza, have now been tested in over 320 people and have had a good safety profile.

About ID Biomedical

ID Biomedical is a North American based biotechnology company focused on the development of proprietary subunit vaccine products, including those based on its Proteosome(TM) platform intranasal adjuvant/delivery technology. ID Biomedical has also developed a proprietary genomics analysis system, Cycling Probe(TM) Technology.

ID Biomedical is developing subunit vaccines for the prevention of a number of different diseases. The Company``s lead products in clinical development are the FluINsure(TM) intranasal influenza (flu) vaccine and the StreptAvax(TM) group A streptococcal vaccine. Additionally, the Company has a number of vaccines in preclinical development.

ID Biomedical is licensing Cycling Probe Technology as well as its broad patents in signal amplification to the genomics and diagnostic industry for further product and technology development. Several companies have obtained rights to ID Biomedical``s patent portfolio.

The foregoing information contains so-called forward-looking statements. These include statements about ID Biomedical``s expectations, beliefs, intentions or strategies for the future, which it indicates by words or phrases such as "anticipate", "expect", "intend", "plan", "will", "we believe", "ID Biomedical believes", "management believes" and similar language. All forward-looking statements are based on ID Biomedical``s current expectations and are subject to risks uncertainties and to assumptions made. Important factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include: (i) the ability to successfully complete preclinical and clinical development of its products; ii) the ability to obtain and enforce timely patent and intellectual property protection for its technology and products; iii) the ability to avoid, either by product design, licensing arrangement or otherwise, infringement of third parties`` intellectual property; iv) decisions, and the timing of decisions, made by the health regulatory agencies regarding approval of its products for human testing; v) the ability to complete and maintain corporate alliances relating to the development and commercialization of its technology and products; vi) market acceptance of its technology and product; and (vii) the competitive environment and impact of technological change. ID Biomedical bases its forward-looking statements on information currently available to it, and assumes no obligation to update them.

Contacts: ID Biomedical Corporation Dean Linden Manager, Corporate Communications [phone] www.idbiomedical.com

ID Biomedical Corporation

© PR Newswire